Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.60 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30070924 | 1.00 | TSHR (0.60) | TSHRCYP2A6CYP1A2HSD17B10ALDH1A1 | |
| Boric Acid SCHEMBL29263393 | 0.92 | TSHR (0.52) | TSHRCYP2A6CYP1A2HSD17B10ALDH1A1 | |
| SCHEMBL29112083 | 0.89 | HPRT1 (0.59) | TSHRCYP2A6CYP1A2HSD17B10ALDH1A1 | |
| SCHEMBL14134221 | 0.77 | CYP1A2 (0.50) | TSHRCYP2A6CYP1A2HSD17B10ALDH1A1 | |
| SCHEMBL29930545 | 0.75 | ALDH1A1 (0.55) | TSHRCYP2A6CYP1A2HSD17B10ALDH1A1 | |
| SCHEMBL29736830 | 0.75 | CYP2A6 (1.00) | TSHRCYP2A6CYP1A2HSD17B10ALDH1A1 | |
| SCHEMBL28814927 | 0.75 | CYP2A6 (1.00) | TSHRCYP2A6CYP1A2HSD17B10ALDH1A1 | |
| SCHEMBL30366237 | 0.75 | ALDH1A1 (0.55) | TSHRCYP2A6CYP1A2HSD17B10ALDH1A1 | |
| SCHEMBL3836747 | 0.75 | ALDH1A1 (0.55) | TSHRCYP2A6CYP1A2HSD17B10ALDH1A1 | |
| SCHEMBL49861 | 0.75 | CYP2A6 (1.00) | TSHRCYP2A6CYP1A2HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7086050-A | — | — | None | — | — | JP | disclosed |
| WO-2024143491-A1 | COMPOUND EMITTING LIGHT UNDER SPECIFIC CONDITIONS, AND METHOD FOR DETECTING CANCER STEM CELLS USING SAME | 国立大学法人京都大学 | 2024-07-04 | — | — | WO | disclosed |
| WO-2023205719-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2022268066-A1 | PROTEIN DEGRADATION AGENT | 苏州开拓药业股份有限公司 | 2022-12-29 | — | — | WO | disclosed |
| US-11251376-B2 | Heterocyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-02-15 | — | — | US | disclosed |
| US-11133473-B2 | Condensed cyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-09-28 | — | — | US | disclosed |
| US-10998503-B2 | Condensed cyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-05-04 | — | — | US | disclosed |
| WO-2021063346-A1 | KRAS G12C INHIBITOR AND APPLICATION THEREOF | 上海迪诺医药科技有限公司 | 2021-04-08 | — | — | WO | disclosed |
| EP-2841429-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2020-10-21 | — | — | EP | disclosed |
| EP-3404017-B1 | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | NISSAN CHEMICAL IND LTD (JP) | 2020-05-13 | — | — | EP | disclosed |
| WO-2013162072-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-10-31 | — | — | WO | disclosed |
| US-20130109669-A1 | 6-AMINO-PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH BIND TO THE SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR FOR THE TREATMENT OF MULTIPLE SCLEROSIS | MERCK SERONO SA (CH) | 2013-05-02 | — | — | US | disclosed |
| US-20060241132-A1 | Spiro derivatives and adhesion molecule inhibitors comprising the same as active ingredient | TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) | 2006-10-26 | — | — | US | disclosed |
| EP-1489081-A1 | SPIRO DERIVATIVES AND ADHESION MOLECULE INHIBITORS COMPRISING THE SAME AS THE ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2004-12-22 | — | — | EP | disclosed |
| US-5643925-A | COGNITION ACTIVATORS AND NERVE GROWTH FACTORS | SANKYO COMPANY, LIMITED (JP) | 1997-07-01 | — | — | US | disclosed |
| US-5614521-A | NERVE GROWTH FACTOR | SANKYO COMPANY, LIMITED (JP) | 1997-03-25 | — | — | US | disclosed |
| EP-0501656-B1 | New benzene derivatives having (NGF) production-promoting activity | SANKYO CO (JP) | 1997-01-22 | — | — | EP | disclosed |
| JP-H0786050-A | GAS-INSULATED ELECTRICAL APPARATUS | OSAKA GAS CO LTD | 1995-03-31 | — | — | JP | disclosed |
| EP-0501656-A2 | New benzene derivatives having (NGF) production-promoting activity | Sankyo Company Limited (JP) | 1992-09-02 | — | — | EP | disclosed |
| US-4443462-A | Antipsychotic 4-(naphthalenyloxy)piperidine derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1984-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11133473-B2 | Condensed cyclic compound and organic light-emitting device including the same | C1S, C1R, CCNA1 | TSHR 3358/4885CYP2A6 1803/4885CYP1A2 985/4885 |
| US-11251376-B2 | Heterocyclic compound and organic light-emitting device including the same | LAGE3, DDT, AOC2 | TSHR 3994/4885CYP2A6 897/4885CYP1A2 30/4885 |
| US-20130109669-A1 | 6-AMINO-PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH BIND TO THE SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR FOR THE TREATMENT OF MULTIPLE SCLEROSIS | S1PR1, S1PR5, S1PR3 | TSHR 251/4885CYP2A6 2083/4885CYP1A2 3836/4885 |
| US-20060241132-A1 | Spiro derivatives and adhesion molecule inhibitors comprising the same as active ingredient | VCAM1, SELL, ICAM1 | TSHR 4388/4885CYP2A6 1185/4885CYP1A2 2159/4885 |
| US-10998503-B2 | Condensed cyclic compound and organic light-emitting device including the same | CRY1, CRY2, LAGE3 | TSHR 4744/4885CYP2A6 3586/4885CYP1A2 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.